December 07, 2016
Two-thirds of patients with chronic lymphocytic leukemia that progressed on B-cell receptor pathway inhibitors had objective responses to treatment with venetoclax (Venclexta), results of a small open-label trial showed.
December 06, 2016
Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses a phase II trial combining nivolumab (Opdivo) with ibrutinib (Imbruvica) for chronic lymphocytic leukemia (CLL) and richter transformation (RT) during the American Society of Hematology (ASH) Annual Meeting.
December 06, 2016
Combination induction therapy with ibrutinib (Imbruvica) and obinutuzumab (Gazyva) after bendamustine debulking induced a 100% response rate in patients with chronic lymphocytic leukemia (CLL), according to findings from the phase II CLL2-BIG trial.
December 05, 2016
Lenalidomide as maintenance following first-line immunochemotherapy substantially improves progression-free survival in the treatment of patients with high-risk chronic lymphocytic leukemia (CLL), according to interim analysis of the phase III CLLM1 study.
December 05, 2016
Findings from the longest follow-up to date evaluating up to 5 years of ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) show that the agent is safe and effective.
December 04, 2016
Treatment with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica) showed encouraging activity and safety in a small phase II study of patients with chronic lymphocytic leukemia and Richter transformation.